Tekmira Pharmaceuticals Corporation's Partner Presents New Clinical Data For LNP-Enabled Patisiran (ALN-TTR02)
4/28/2014 5:20:13 PM
VANCOUVER, British Columbia, April 28, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) presented new clinical data for patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology. The program represents the most clinically advanced application of Tekmira's proprietary LNP delivery technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by